Novel biomarkers and therapeutic targets for prostate cancer

10.2741/s93 ◽  
2010 ◽  
Vol S2 (2) ◽  
pp. 677-684 ◽  
Author(s):  
Rajesh K Naz
Keyword(s):  
Prostate Cancer ◽  
Therapeutic Targets ◽  
Novel Biomarkers

Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer

2015 ◽  
Vol 19 (1) ◽  
pp. 14-20 ◽  
Author(s):  
V Mouraviev ◽  
B Lee ◽  
V Patel ◽  
D Albala ◽  
T E B Johansen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Noncoding Rnas ◽  
Therapeutic Targets ◽  
Long Noncoding Rnas ◽  
Novel Biomarkers

MicroRNA-Mediated Control of Prostate Cancer Metastasis: Implications for the Identification of Novel Biomarkers and Therapeutic Targets

2013 ◽  
Vol 20 (12) ◽  
pp. 1566-1584 ◽  
Author(s):  
Nicola Fenderico ◽  
Anna Casamichele ◽  
Valentina Profumo ◽  
Nadia Zaffaroni ◽  
Paolo Gandellini
Keyword(s):  
Prostate Cancer ◽  
Cancer Metastasis ◽  
Therapeutic Targets ◽  
Prostate Cancer Metastasis ◽  
Novel Biomarkers

scholarly journals AR Splicing Variants and Resistance to AR Targeting Agents

Cancers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2563
Author(s):  
Mayuko Kanayama ◽  
Changxue Lu ◽  
Jun Luo ◽  
Emmanuel S. Antonarakis
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Splice Variants ◽  
Treatment Options ◽  
Predictive Biomarker ◽  
Castration Resistant Prostate Cancer ◽  
Treatment Benefit ◽  
Novel Biomarkers ◽  
The Many ◽  
Preclinical And Clinical Studies

Over the past decade, advances in prostate cancer research have led to discovery and development of novel biomarkers and effective treatments. As treatment options diversify, it is critical to further develop and use optimal biomarkers for the purpose of maximizing treatment benefit and minimizing unwanted adverse effects. Because most treatments for prostate cancer target androgen receptor (AR) signaling, aberrations affecting this drug target are likely to emerge following the development of castration-resistant prostate cancer (CRPC), and it is conceivable that such aberrations may play a role in drug resistance. Among the many AR aberrations, we and others have been studying androgen receptor splice variants (AR-Vs), especially AR-V7, and have conducted preclinical and clinical studies to develop and validate the clinical utility of AR-V7 as a prognostic and potential predictive biomarker. In this review, we first describe mechanisms of AR-V generation, regulation and their functions from a molecular perspective. We then discuss AR-Vs from a clinical perspective, focusing on the significance of AR-Vs detected in different types of human specimens and AR-Vs as potential therapeutic targets.

scholarly journals Circular RNA Expression Profiling Identifies Prostate Cancer- Specific circRNAs in Prostate Cancer

2018 ◽  
Vol 50 (5) ◽  
pp. 1903-1915 ◽  
Author(s):  
Qianlin Xia ◽  
Tao Ding ◽  
Guihong Zhang ◽  
Zehuan Li ◽  
Ling Zeng ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Polymerase Chain Reaction Analysis ◽  
Circular Rna ◽  
Differentially Expressed ◽  
Pcr Analysis ◽  
High Morbidity ◽  
Qrt Pcr ◽  
Diagnosis And Prognosis ◽  
Novel Biomarkers ◽  
Rna Expression Profiling

Background/Aims: Prostate cancer (PCa) is one of the main cancers that damage males’ health severely with high morbidity and mortality, but there is still no ideal molecular marker for the diagnosis and prognosis of prostate cancer. Methods: To determine whether the differentially expressed circRNAs in prostate cancer can serve as novel biomarkers for prostate cancer diagnosis, we screened differentially expressed circRNAs using SBC-ceRNA array in 4 pairs of prostate tumor and paracancerous tissues. A circRNA-miRNA-mRNA regulatory network for the differential circRNAs and their host genes was constructed by Cytoscape3.5.1 software. Quantitative real-time polymerase chain reaction analysis (qRT-PCR) was performed to confirm the microarray data. Results: We found 1021 differentially expressed circRNAs in PCa tumor using SBC-ceRNA array and confirmed the expression of circ_0057558, circ_0062019 and SLC19A1 in PCa cell lines and tumor tissues through qRT-PCR analysis. We demonstrated that combination of PSA level and two differentially expressed circRNAs showed significantly increased AUC, sensitivity and specificity (0.938, 84.5% and 90.9%, respectively) than PSA alone (AUC of serum PSA was 0.854). Moreover, circ_0057558 was correlated positively with total cholesterol. The functional network of circRNA-miRNA-mRNA analysis showed that circ_0057558 and circ_0034467 regulated miR-6884, and circ_0062019 and circ_0060325 regulated miR-5008. Conclusion: Our results demonstrated that differentially expressed circRNAs (circ_0062019 and circ_0057558) and host gene SLC19A1 of circ_0062019 could be used as potential novel biomarkers for prostate cancer.

scholarly journals Molecular Alterations in Prostate Cancer as Diagnostic, Prognostic, and Therapeutic Targets

2008 ◽  
Vol 15 (6) ◽  
pp. 319-331 ◽  
Author(s):  
Bora Gurel ◽  
Tsuyoshi Iwata ◽  
Cheryl M. Koh ◽  
Srinivasan Yegnasubramanian ◽  
William G. Nelson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Therapeutic Targets ◽  
Molecular Alterations

scholarly journals STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer

Oncotarget ◽  
2017 ◽  
Vol 8 (49) ◽  
pp. 85997-86010 ◽  
Author(s):  
Sambit K. Mohanty ◽  
Kader Yagiz ◽  
Dinesh Pradhan ◽  
Daniel J. Luthringer ◽  
Mahul B. Amin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Therapeutic Targets ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

scholarly journals Mechanisms of Action And Clinical Implications of MicroRNAs in the Drug Resistance of Gastric Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Ying Liu ◽  
Xiang Ao ◽  
Guoqiang Ji ◽  
Yuan Zhang ◽  
Wanpeng Yu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Drug Resistance ◽  
Molecular Mechanisms ◽  
Malignant Tumors ◽  
Life Quality ◽  
Therapeutic Targets ◽  
Chemotherapeutic Agents ◽  
Response To Chemotherapy ◽  
Novel Biomarkers ◽  
Related Proteins

Gastric cancer (GC) is one of the most common malignant tumors of digestive systems worldwide, with high recurrence and mortality. Chemotherapy is still the standard treatment option for GC and can effectively improve the survival and life quality of GC patients. However, with the emergence of drug resistance, the clinical application of chemotherapeutic agents has been seriously restricted in GC patients. Although the mechanisms of drug resistance have been broadly investigated, they are still largely unknown. MicroRNAs (miRNAs) are a large group of small non-coding RNAs (ncRNAs) widely involved in the occurrence and progression of many cancer types, including GC. An increasing amount of evidence suggests that miRNAs may play crucial roles in the development of drug resistance by regulating some drug resistance-related proteins as well as gene expression. Some also exhibit great potential as novel biomarkers for predicting drug response to chemotherapy and therapeutic targets for GC patients. In this review, we systematically summarize recent advances in miRNAs and focus on their molecular mechanisms in the development of drug resistance in GC progression. We also highlight the potential of drug resistance-related miRNAs as biomarkers and therapeutic targets for GC patients.

Sign in / Sign up

Export Citation Format

Share Document